title: Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients.
abstract: OBJECTIVE
  To propose an alternative approach for treatment of pulmonary marginal zone lymphoma, using a very small radiation dose (2 × 2 Gy) delivered exclusively to tumor sites.
  
  
  METHODS
  Patients had localized pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma according to the World Health Organization classification. The 6-MV radiation treatments were delivered using tumor-limited fields, except in cases of diffuse bilateral involvement. Two daily fractions of 2 Gy were delivered to tumor-limited fields using a 6-MV linear accelerator.
  
  
  RESULTS
  Ten patients with pulmonary MALT lymphoma entered the study. All but 1 had localized tumor masses. The median follow-up was 56 months (range, 2-103 months). Complete remission or an unconfirmed complete remission was obtained in 60% of patients within the first 2 months, and two additional partial responses were converted into a long-term unconfirmed complete remission. All patients are well and alive, no local progression was observed, and the 5-year progression-free survival rate was 87.5% (95% confidence interval 49%-97%).
  
  
  CONCLUSIONS
  Our results suggest that extremely low radiation doses delivered exclusively to tumor sites might be a treatment option in pulmonary MALT lymphoma.
authors.affiliation: Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France. girinsky@igr.fr
authors.forename: Theodore
authors.initials: T
authors.lastname: Girinsky
authors.forename: Amaury
authors.initials: A
authors.lastname: Paumier
authors.forename: Christophe
authors.initials: C
authors.lastname: Ferme
authors.forename: Colette
authors.initials: C
authors.lastname: Hanna
authors.forename: Vincent
authors.initials: V
authors.lastname: Ribrag
authors.forename: François
authors.initials: F
authors.lastname: Leroy-Ladurie
authors.forename: Mithra
authors.initials: M
authors.lastname: Ghalibafian
mesh_terms: D000328:Adult; D000368:Aged; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012074:Remission Induction / Q000379:methods; D015996:Survival Rate; D016896:Treatment Outcome